EC20 imaging predicts response in a randomized trial comparing pegylated liposomal doxorubicin (PLD) +/- EC145 in platinum-resistant ovarian cancer.

Authors
Category Primary study
Year 2011
This article has no abstract
Epistemonikos ID: 673d1e7c7a96e91b7fab49af0d43a88f4cfba4d4
First added on: May 12, 2020